Published in Eur Urol on December 02, 2009
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol (2014) 1.14
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J (2016) 1.08
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93
Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol (2011) 0.90
A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc (2012) 0.85
Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.85
Emerging optical techniques in advanced cystoscopy for bladder cancer diagnosis: A review of the current literature. Indian J Urol (2011) 0.83
Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am (2015) 0.82
Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer. Biomed Res Int (2015) 0.82
Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. Ther Adv Urol (2014) 0.81
Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol (2012) 0.81
Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials (2016) 0.78
Emerging endoscopic imaging technologies for bladder cancer detection. Curr Urol Rep (2014) 0.78
New frontier in hypericin-mediated diagnosis of cancer with current optical technologies. Ann Biomed Eng (2011) 0.76
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? Bladder Cancer (2015) 0.75
The role of transcavitary ultrasonography in diagnosis and staging of nonmuscle-ınvasive bladder cancer: a prospective non-randomized clinical study. Springerplus (2014) 0.75
Approaching the optimal transurethral resection of a bladder tumor. Turk J Urol (2014) 0.75
Are we closer to seeing carcinoma in situ in the upper urinary tract? Cent European J Urol (2016) 0.75
Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol (2015) 0.75
Systematic support for photodynamic diagnosis. Nat Rev Urol (2010) 0.75
HIF-1, GLUT1, endoglin, and BIRC5 expression in urine samples obtained from patients with bladder malignancies - after photodynamic diagnosis (PDD). Cent European J Urol (2012) 0.75
Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer (2016) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One (2010) 7.48
Statistical analysis of rare sequence variants: an overview of collapsing methods. Genet Epidemiol (2011) 6.18
Gene map of the extended human MHC. Nat Rev Genet (2004) 6.01
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
The epidemiology of renal cell carcinoma. Eur Urol (2011) 3.85
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18
A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18
Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
On safari to Random Jungle: a fast implementation of Random Forests for high-dimensional data. Bioinformatics (2010) 3.09
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91
A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature (2010) 2.88
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol (2010) 2.82
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) (2007) 2.69
A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur Urol (2007) 2.68
Urinary diversion. Urology (2007) 2.65
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet (2011) 2.62
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series. Int J Radiat Oncol Biol Phys (2011) 2.55
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol (2013) 2.48
Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol (2012) 2.45
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol (2012) 2.43
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS One (2008) 2.37
Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity? Eur Urol (2007) 2.33
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
Laparoendoscopic single-site and natural orifice transluminal endoscopic surgery in urology: a critical analysis of the literature. Eur Urol (2010) 2.28
BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol (2005) 2.26
Grasping molecular structures through publication-integrated 3D models. Trends Biochem Sci (2008) 2.26
Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. Eur Urol (2007) 2.24
SNP-based analysis of genetic substructure in the German population. Hum Hered (2006) 2.21
Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol (2011) 2.20
Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. Urology (2011) 2.20
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Bulbar urethroplasty using buccal mucosa grafts placed on the ventral, dorsal or lateral surface of the urethra: are results affected by the surgical technique? J Urol (2005) 2.19
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. Eur Urol (2012) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur Urol (2007) 2.16
Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology (2010) 2.15
A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol (2010) 2.13
Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry (2006) 2.13
Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int (2012) 2.10